Politics Versus Science in Biomedical Research and Development

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology-07-02-2004
Volume 28
Issue 7

Decisions to accelerate the approval of AIDS combination drugs, reject the over-the-counter status for the morning-after pill, and limit support for stem cell research are hot political topics.

External Link - article-103357.pdf

Articles in this issue
i1-143861-1408695852146.jpg
3M Drug Delivery Systems
i1-143960-1408695698259.jpg
AccuRate
July 2004
Characterization of the Performance of Bin Blenders Part 2 of 3: Free-Flowing Mixtures
Investors Shy Away from Pharmaceutical Chemicals
From CGMPs to the Critical Path: FDA Focuses on Innovation, Quality, and Continuous Improvement–Inside and Out
In the Spotlight-July 2004
The LR Method in Critical Areas: Airflow Patterns and the Design of Aseptic Interventions
A Stability Program for the Distribution of Drug Products
Politics Versus Science in Biomedical Research and Development
Recent Videos
CPHI Milan 2024: Compliance and Automation in Aseptic Processing
Related Content
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

PTC Therapeutics Gains FDA Approval for AADC Deficiency Gene Therapy

Feliza Mirasol
November 19th 2024
Article

FDA's approval of eladocagene exuparvovec-tneq (Kebilidi) makes that product the first FDA-approved gene therapy for treating AADC deficiency.

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

J&J’s Balversa Gains MHRA Marketing Authorization as Monotherapy for Bladder Cancer

Feliza Mirasol
November 8th 2024
Article

Balversa (erdafitinib) marks the first and only bladder cancer therapy to target FGFR3 alterations, with a demonstrated increase in overall survival from 7.8 months to 12.1 months.

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
May 28th 2024
Podcast

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.

Medium shot of female process supervisor in lab coat pointing at equipment controlling production quality with African American male manufacturing technician, working in protective suit at factory | Image Credit: © Seventyfour - © Seventyfour - stock.adobe.com

Application of Validation Principles to the Training Quality System: Part 9, Quality Risk Management Hazard Identification

Paul L. Pluta
November 8th 2024
Article

Pharmaceutical training programs are enhanced by integrating ICH quality risk management considerations.

Question mark background | Image Credit: © Leigh-Prather - © Leigh Prather - stock.adobe.com

The Importance of Appropriate Supplier Oversight

Siegfried Schmitt
November 2nd 2024
Article

The product license holder must have a supplier oversight system in place, says Siegfried Schmitt, PhD, vice president, Technical, Parexel.